Vrelysin is under clinical development by Intralytix and currently in Phase II for Vancomycin-Resistant Enterococcus faecium Infections. According to GlobalData, Phase II drugs for Vancomycin-Resistant Enterococcus faecium Infections does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Vrelysin LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Vrelysin overview

Vrelysin is under development for the treatment of vancomycin resistant Enterococcus (VRE) infections. The therapeutic candidate comprises of a cocktail of lytic Enterococcus-specific bacteriophages, administered orally.

Intralytix overview

Intralytix is a biotechnology company that develops, produces and markets bacteriophage based products to control bacterial pathogens. It offers food safety products, pet food safety products and pre-harvest interventions. Its food safety products include listshield, ecoshield, salmofresh and shigashield. Intralytix food safety products help prevent Listeria monocytogenes and Escherichia coli contamination in food and food processing facilities. Its animal health products are effective against Clostridium perfringens contamination in live poultry. The company also commercializes its bacteriophage technology for use in food production and processing, environmental cleanliness, veterinary applications and human therapy. Intralytix is headquartered in Baltimore, Maryland, the US.

For a complete picture of Vrelysin’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.